Skip to main content
. Author manuscript; available in PMC: 2014 Mar 13.
Published in final edited form as: Leuk Lymphoma. 2013 Jun 24;55(2):337–341. doi: 10.3109/10428194.2013.803547

Figure 1.

Figure 1

Patients who received carfilzomib or pomalidomide after T0 had an improved median overall survival (12.6 months) compared to those without carfilzomib or pomalidomide (6.8 months) (p=0.03 by Wilcoxon test). Figure footnote:Abbreviations: OS- overall survival; Carf- carfilzomib; Pom- pomalidomide.